| Name | Title | Contact Details |
|---|---|---|
Charles Blackmore |
Chief Information Security Officer | Profile |
Continental is a Germany-based automotive company that manufactures and distributes products such as tires, brake systems and chassis components for the transportation sector.
MFR Consultants, Inc. (MFR), a full-service management consulting firm headquartered in Philadelphia, PA, has provided end-to-end solutions in the areas of business analysis, information technology, project management and information governance for over 30 years.
The space between starting a business and scaling one…is TrueSpace. TrueSpace is a professional learning community for Founders and their leadership teams. We teach a new model of business building to change how entrepreneurs use their time, invest capital and lead talent. TrueSpace is the leading authority on the operating conditions necessary to prepare a business for scale. Weve put in the time, money, and hard work to make this claim and have the broadest set of data on companies between $1 - $10M. By joining our community you gain: 1. Predictive Insight - see your business and its potential through a scientific lens 2. Resource Clarity - make more accurate decisions with your use of time, capital, and talent 3. A Curated Community - be a valuable addition to a national network of Business Builders® 4. National Recognition - get discovered by investors, top talent, and potential buyers Apply today at www.truespace.com
storyoftheseason.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.